METHODS INCLUDING NEUTROPHILE ELASTICITY INHIBITOR ALBELESTAT FOR TREATMENT OF RESPIRATORY DISEASE CAUSED BY ALPHA-1 ANTITRYPSIN DEFICIENCY
CY1126284T1Undetermined Publication Date: 2026-07-31MEREO BIOPHARMA 4 LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CY20231100611T
- Authority / Receiving Office
- CY · CY
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-08-04
- Filing Date
- 2023-11-01
- Publication Date
- 2026-07-31
- Estimated Expiration
- 2043-11-01
Abstract
The present invention discloses a dosage form and dosage regimen of 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (i.e. albelestat) or salts thereof, and related methods of using the dosage form and dosage regimen.
Need to check novelty before this filing date? Find Prior Art